Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

BACKGROUND: Doravirine is a novel, nonnucleoside reverse transcriptase inhibitor with demonstrated efficacy in treatment-naive adults with HIV-1. METHODS: In this open-label, active-controlled, noninferiority trial, adults with HIV-1 virologically suppressed for ≥6 months on 2 nucleoside reverse tra...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Acquir Immune Defic Syndr
Autors principals: Johnson, Margaret, Kumar, Princy, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J., Hwang, Carey, Greaves, Wayne
Format: Artigo
Idioma:Inglês
Publicat: JAIDS Journal of Acquired Immune Deficiency Syndromes 2019
Matèries:
Clinical Science
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6905402/
https://ncbi.nlm.nih.gov/pubmed/30985556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002056
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars